About Acomplia
Sanofi Aventis, a large cap French pharmaceutical firm developed an effectual weight loss medication, Acomplia. This weight loss medication is to be employed is association with a proper diet plan and regular exercise regime to attain effective results.
Acomplia is a Sanofi
Aventis creation, which is a large cap French pharmaceutical firm. Weight loss
medication Acomplia is a product of
2 years of clinical trials undertaken in
Weight loss is not the only benefit which is sourced by use of this diet pill.
Usage of this weight loss medication has also proven to be beneficial in
improvement of cardio-metabolic risk factors, smoking cessation, and even
minimization of chances of weight gain.
This weight loss medication has been in the news
ever since its launch in the year 2006. At present, it is approved for sale in
the
and even UAE amid other countries.
Although it hasn’t yet
received FDA approval for sale in the
the US Zimulti has already been decided. Sanofi
Aventis is hopeful about its approval in the future, for which a fresh
50-month trials are already on their way, estimated to be completed in the year
2010. It seems that it would be until these trials are completed that the FDA
would reconsider its decision on usage of this diet pill in the
It works upon the mechanism
of appetite suppressant, and in this way beneficial in weight loss. Excessive
desire to eat is the prime reason for weight gain, a medication which could
reduce this urge can effectively facilitate trimming down of your body shape. Use
of this medication is suggested to be employed with a proper diet plan and
regular exercise plan for attainment of desired results.
Usage of this medication
is intended for individuals with a BMI 30; or BMI 27 along with obesity related
risk factors such as high cholesterol or type 2 diabetes. In order to ascertain
the suitability of the medication, speak with your general practitioner before
initiating this weight loss medication.